Buprenorphine Pharmacology Related to Addiction Treatment - 18
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000236
Collaborator
University of Vermont (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Buprenorphine Pharmacology Related to Addiction Treatment
Outcome Measures
Primary Outcome Measures
- Drug use []
- Opioid agonist effects []
- Opiate withdrawal []
- Psychological changes in: pupil diameter, blood pressure, heart rate, respiration []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Treatment Research Center | Burlington | Vermont | United States | 05401 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Vermont
Investigators
- Principal Investigator: Warren Bickel, Ph.D., University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000236
Other Study ID Numbers:
- NIDA-06969-18
- R01-06969-18
First Posted:
Sep 21, 1999
Last Update Posted:
Aug 17, 2005
Last Verified:
Dec 1, 2002
Additional relevant MeSH terms: